Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HDM-SPIRE
- Development stage
- Phase 2
- Lead developer
- NIOX
- Modality
- Peptides, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
HDM-SPIRE is a synthetic peptide-based intradermal immunotherapy developed for the treatment of house dust mite-induced allergic rhinoconjunctivitis. It consists of short peptides derived from major house dust mite allergens, designed to induce immune tolerance by modulating T-cell responses. The mechanism involves binding to MHC class II molecules on antigen-presenting cells, leading to upregulation of regulatory T-cells and suppression of IgE-mediated allergic responses. This approach aims to reduce the risk of IgE-mediated side effects compared with traditional allergen immunotherapies and potentially offers a shorter course of treatment. The drug was originally developed by Circassia (now NIOX), but development for allergic rhinoconjunctivitis has been discontinued after phase 2 trials[1][6][8].
- Brand names
- ToleroMune HDMHDM-SPIRE
- Other names
- Antiallergy vaccine house dust miteHouse dust mite allergy immunotherapyHouse dust mite allergy vaccine
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on HDM-SPIRE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HDM-SPIRE.